Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80525 |
Name | differentiated high-grade thyroid carcinoma |
Definition | A thyroid gland adenocarcinoma characterized by extensive evidence of follicular cell differentiation. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated high-grade thyroid carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS mutant | Pazopanib + Trametinib | differentiated high-grade thyroid carcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | differentiated high-grade thyroid carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | differentiated high-grade thyroid carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03732495 | Phase II | Denosumab + Lenvatinib | Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) | Unknown status | FRA | 0 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04544111 | Phase II | Dabrafenib + Spartalizumab Spartalizumab + Trametinib | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT05783323 | Phase II | Larotrectinib | Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT06235216 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab govitEcan in THYroid Cancers (SETHY) | Recruiting | ESP | 0 |